Cathy Chognot

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

Amit Bar‐Or, Jonathan Calkwood, Cathy Chognot et al. · Neurology · 2020 · 339 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

Robert R. Henry, A. Michael Lincoff, Sunder Mudaliar et al. · The Lancet · 2009 · 204 citations

Medicine, Endocrinology, Pharmacology +17

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Stephen L. Hauser, Ludwig Kappos, Xavier Montalbán et al. · Neurology · 2021 · 177 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Epidemiology +15

Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002)

Daniela Stokmaier, Kevin Winthrop, Cathy Chognot et al. · Neurology · 2018 · 26 citations

Life Sciences, Immunology, Neurology +15

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

João Cerqueira, Achim Berthele, Bruce Cree et al. · Neurology · 2025 · 23 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17